JCXH-211 is under clinical development by Immorna Hangzhou Biotechnology and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how JCXH-211’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
JCXH-211 is under development for the treatment of malignant solid tumor, head and neck cancer, liver cancer, melanoma, triple-negative breast cancer, esophageal cancer and glioblastoma multiforme. The drug candidate is a lipid nanoparticle (LNP) encapsulated self-replicating mRNA encoding the human interleukin 12 (IL12) protein. It is administered by intratumor route as injection.
Immorna Hangzhou Biotechnology overview
Immorna Hangzhou Biotechnology (Immorna) is an healthcare service provider which focuses on research and development in the fields of oncology and focuses to offer other related services. Immorna is headquartered in Hangzhou, Zhejiang, China.
For a complete picture of JCXH-211’s drug-specific PTSR and LoA scores, buy the report here.